Merck Reports Five-Year KEYNOTE-024 Data for Keytruda in PD-L1 High NSCLC

Merck today presented five-year overall survival data from the Phase 3 KEYNOTE-024 trial evaluating Keytruda (pembrolizumab) versus platinum-based chemotherapy in patients with previously untreated metastatic non-small cell lung cancer with PD-L1 TPS ≥50%. The data showed that 31.9% of patients in the Keytruda arm were alive at five years compared to 16.3% in the chemotherapy arm.